RECORD-3 II期研究最终总生存分析:转移性肾细胞癌一线依维莫司序贯舒尼替尼对比一线舒尼替尼序贯依维莫司
RECORD-3研究比较转移性肾细胞癌一线依维莫司后序贯舒尼替尼与反向标准序列(一线舒尼替尼后序贯依维莫司)的疗效。最终总生存分析显示,依维莫司-舒尼替尼组中位OS为22.4个月,舒尼替尼-依维莫司组为29.5个月(HR 1.1,95%CI 0.9-1.4)。结果支持转移性肾细胞癌进展后采用舒尼替尼序贯依维莫司。
要点
- 最终OS分析支持mRCC患者进展后采用舒尼替尼序贯依维莫司。
- 依维莫司-舒尼替尼组中位OS 22.4个月 vs 舒尼替尼-依维莫司组29.5个月(HR 1.1,95%CI 0.9-1.4)。
- 二线治疗相关3/4级不良事件率:依维莫司47% vs 舒尼替尼57%。
核心结论
- 最终OS分析结果支持转移性肾细胞癌患者进展后采用舒尼替尼序贯依维莫司的治疗顺序。
- 依维莫司和舒尼替尼的安全性特征与既往报告一致,未出现非预期安全性信号。
研究设计与样本
- RECORD-3为II期研究,患者接受一线依维莫司进展后二线舒尼替尼(n=238)或一线舒尼替尼进展后二线依维莫司(n=233)。
- 次要终点包括一线联合二线无进展生存期(PFS)、总生存期(OS)和安全性。
- 探索了中性粒细胞淋巴细胞比值(NLR)和基线可溶性生物标志物水平对OS的影响。
主要发现
- 最终分析时,依维莫司中位暴露时间5.6个月,舒尼替尼8.3个月。
- 中位联合PFS:依维莫司-舒尼替尼组21.7个月(95%CI 15.1-26.7) vs 舒尼替尼-依维莫司组22.2个月(95%CI 16.0-29.8),HR(EVE-SUN/SUN-EVE)1.2(95%CI 0.9-1.6)。
- 中位OS:依维莫司-舒尼替尼组22.4个月(95%CI 18.6-33.3) vs 舒尼替尼-依维莫司组29.5个月(95%CI 22.8-33.1),HR(EVE-SUN/SUN-EVE)1.1(95%CI 0.9-1.4)。
- 疑似与二线治疗相关的3级和4级不良事件率:依维莫司47% vs 舒尼替尼57%。
- 较高的NLR和12种可溶性生物标志物水平被确定为OS不良的预后标志物,其关联很大程度上独立于治疗顺序。
关键数值与推荐
- 中位联合PFS:依维莫司-舒尼替尼组21.7个月(95%CI 15.1-26.7) vs 舒尼替尼-依维莫司组22.2个月(95%CI 16.0-29.8),HR 1.2(95%CI 0.9-1.6)。
- 中位OS:依维莫司-舒尼替尼组22.4个月(95%CI 18.6-33.3) vs 舒尼替尼-依维莫司组29.5个月(95%CI 22.8-33.1),HR 1.1(95%CI 0.9-1.4)。
- 疑似与二线治疗相关的3级和4级不良事件率:依维莫司47% vs 舒尼替尼57%。
临床怎么用
- 原文结论支持转移性肾细胞癌患者进展后采用舒尼替尼序贯依维莫司的治疗顺序。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: RECORD-3 compared everolimus and sunitinib as first-line therapy, and the sequence of everolimus followed by sunitinib at progression compared with the opposite (standard) sequence in patients with metastatic renal cell carcinoma (mRCC). This final overall survival (OS) analysis evaluated mature data for secondary end points. PATIENTS AND METHODS: Patients received either first-line everolimus followed by second-line sunitinib at progression (n = 238) or first-line sunitinib followed by second-line everolimus (n = 233). Secondary end points were combined first- and second-line progression-free survival (PFS), OS, and safety. The impacts of neutrophil lymphocyte ratio (NLR) and baseline levels of soluble biomarkers on OS were explored. RESULTS: At final analysis, median duration of exposure was 5.6 months for everolimus and 8.3 months for sunitinib. Median combined PFS was 21.7 months [95% confidence interval (CI) 15.1-26.7] with everolimus-sunitinib and 22.2 months (95% CI 16.0-29.8) with sunitinib-everolimus [hazard ratio (HR)EVE-SUN/SUN-EVE, 1.2; 95% CI 0.9-1.6]. Median OS was 22.4 months (95% CI 18.6-33.3) for everolimus-sunitinib and 29.5 months (95% CI 22.8-33.1) for sunitinib-everolimus (HREVE-SUN/SUN-EVE, 1.1; 95% CI 0.9-1.4). The rates of grade 3 and 4 adverse events suspected to be related to second-line therapy were 47% with everolimus and 57% with sunitinib. Higher NLR and 12 soluble biomarker levels were identified as prognostic markers for poor OS with the association being largely independent of treatment sequences. CONCLUSIONS: Results of this final OS analysis support the sequence of sunitinib followed by everolimus at progression in patients with mRCC. The safety profiles of everolimus and sunitinib were consistent with those previously reported, and there were no unexpected safety signals. CLINICAL TRIALS NUMBER: ClinicalTrials.gov identifier, NCT00903175.
引用
- Knox JJ, Barrios CH, Kim TM, et al. Final overall survival analysis for the phase II RECORD-3 study of first-line everolimus followed by sunitinib versus first-line sunitinib followed by everolimus in metastatic RCC. Ann Oncol. 2017. PMID: 28327953. doi:10.1093/annonc/mdx075
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。